During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled receptors in living cells actually respond to activating substances. The ...

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer Corcept Therapeutics ...

Opioid antagonists are medications people can take to treat opioid use disorder. They help by reducing withdrawal symptoms, addressing cravings, and managing overdoses. Doctors prescribe opioid ...

In this segment, Dr. Gregory Vidal discusses the role of estrogen receptor antagonists in the treatment of ER-positive, ...